A Multi-Center Double-Blind Parallel-Group Comparison Study in Involutional Osteoporosis Patients to Examine the Efficacy and Safety of ONO-5920/YM529 Monthly Intermittent Formulation With Its Daily Formulation.
Phase of Trial: Phase II/III
Latest Information Update: 07 May 2015
At a glance
- Drugs Minodronic acid (Primary)
- Indications Osteoporosis
- Focus Biomarker; Therapeutic Use
- Sponsors Astellas Pharma
- 08 Jul 2010 Actual end date (April 2010) added as reported by ClinicalTrials.gov.
- 08 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 May 2009 Actual patient number (692) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History